A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
作者信息
Pleyer Christopher, Tian Xin, Rampertaap Shakuntala, Mu Rui, Soto Susan, Superata Jeanine, Gaglione Erika, Sun Clare, Lotter Jennifer, Stetler-Stevenson Maryalice, Yuan Constance M, Maric Irina, Pittaluga Stefania, Rosenzweig Sergio, Fleisher Thomas, Wiestner Adrian, Ahn Inhye E
机构信息
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
出版信息
Am J Hematol. 2020 Nov;95(11):E310-E313. doi: 10.1002/ajh.25968. Epub 2020 Sep 8.
Abstract
摘要
相似文献
1
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Am J Hematol. 2020 Nov;95(11):E310-E313. doi: 10.1002/ajh.25968. Epub 2020 Sep 8.
2
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2024 Jun;25(6):744-759. doi: 10.1016/S1470-2045(24)00196-7.
3
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Lancet Haematol. 2019 Aug;6(8):e419-e428. doi: 10.1016/S2352-3026(19)30104-8. Epub 2019 Jun 14.
4
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
5
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Leukemia. 2021 Dec;35(12):3421-3429. doi: 10.1038/s41375-021-01280-8. Epub 2021 May 18.
6
Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada.
Leuk Res. 2021 Apr;103:106538. doi: 10.1016/j.leukres.2021.106538. Epub 2021 Feb 18.
7
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood. 2021 Feb 25;137(8):1019-1023. doi: 10.1182/blood.2020008164.
8
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.
9
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Hematol Oncol. 2019 Apr;37(2):185-192. doi: 10.1002/hon.2580. Epub 2019 Mar 12.
10
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Br J Cancer. 2020 Jul;123(2):240-251. doi: 10.1038/s41416-020-0887-6. Epub 2020 May 18.
引用本文的文献
1
Maintenance therapy for chronic lymphocytic leukaemia.
Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD013474. doi: 10.1002/14651858.CD013474.pub2.
2
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.
J Hematol Oncol. 2022 Oct 1;15(1):138. doi: 10.1186/s13045-022-01353-w.
3
Targeting Bruton's Tyrosine Kinase in CLL.
Front Immunol. 2021 Jun 23;12:687458. doi: 10.3389/fimmu.2021.687458. eCollection 2021.
本文引用的文献
1
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
Blood. 2020 Feb 13;135(7):510-513. doi: 10.1182/blood.2019003570.
2
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
3
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.
4
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.
5
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Blood. 2018 May 24;131(21):2357-2366. doi: 10.1182/blood-2017-12-820910. Epub 2018 Feb 26.
Zotero 插件